Navigation Links
Tracon Pharmaceuticals to Present Clinical Stage Programs at AACR 2009
Date:2/17/2009

SAN DIEGO, Feb. 17 /PRNewswire/ -- Tracon Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and related diseases, announced today that its three clinical stage cancer therapeutics (TRC105, TRC102, and TRC093) will be presented at the 100th Annual Meeting of the American Association for Cancer Research this April 18-22 in Denver, Colorado. "Each program targets a unique pathway with the potential for broad application to a wide variety of cancer types, and we are pleased that all three will be presented at this year's meeting" explained Bryan Leigh, MD, Chief Medical Officer at Tracon Pharmaceuticals.

TRC105 is a chimeric IgG1 monoclonal antibody that binds CD105, a membrane receptor required for angiogenesis. By inhibiting new blood vessel formation, the antibody is expected to have activity against a wide variety of solid tumors that rely on angiogenesis to grow and metastasize. Clinical data from a phase 1 first-in-human study of TRC105 therapy for advanced cancer was recently presented at the 11th International Symposium on Anti-Angiogenic Agents in San Diego, CA by Michael S. Gordon, MD (Premiere Oncology, Scottsdale, AZ). TRC105 may also be a useful therapy for age-related macular degeneration, the most common cause of blindness in people over the age of 50.

TRC102 is a small molecule inhibitor of base excision repair that improves the therapeutic index of commonly used antimetabolite and alkylating agent chemotherapies. The molecule is currently being studied as an oral agent in combination with pemetrexed (Alimta(R)) and as an i.v. agent in combination with temozolomide (Temodar(R)).

TRC093 is a humanized IgG1 monoclonal antibody that inhibits angiogenesis, tumor growth, and metastasis by binding cleaved collagen in the extracellular matrix of cancers. This antibody is expected to address multiple solid tumor types and may also be developed for age-related macular degeneration. The phase 1 first-in-human study of TRC093 monotherapy is nearly complete, and a phase 2 dose range has been identified for future studies.

The presentation details are as follows:

TRC105

Abstract Title: Preclinical pharmacokinetic and pharmacodynamic data for TRC105 (anti-endoglin antibody) are consistent with clinical activity observed at low doses in patients with advanced cancer

Presenter: Charles Theuer, MD, PhD, Tracon Pharmaceuticals

Date and Time: Sunday, April 19, 2009, 1:00 PM

Abstract Number: 1237

TRC102

Abstract Title: Unexpected prolonged half life of the base-excision repair inhibitor methoxyamine given with temozolomide in the first-in-human phase 1 clinical trial

Presenter: Panayiotis Savvides, MD, PhD, MPH, Case Comprehensive Cancer Center

Date and Time: Wednesday, April 22, 2009, 8:00 AM

Abstract Number: 5433

TRC093

Abstract Title: Targeting the HU177 cryptic collagen epitope with humanized antibody TRC093 functions cooperatively with anti-VEGF therapy to inhibit tumor growth

Presenter: Jennifer M. Roth, PhD, Maine Medical Center Research Institute

Date and Time: Sunday, April 19, 2009, 8:00 AM

Abstract Number: 317

About Tracon

Tracon Pharmaceuticals (www.traconpharma.com) is a privately held biotechnology company focused on the development of products for oncology and ophthalmology treatment, including agents that inhibit angiogenesis. Tracon addresses unmet needs in these areas with first-in-class product candidates that will complement existing therapies. Further information about Tracon Pharmaceuticals can be found at www.traconpharma.com.

    Contact
    Alison Fishman, Tracon Pharmaceuticals, Inc.
    afishman@traconpharma.com
    858-550-0780


'/>"/>
SOURCE Tracon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. The Effects of Probiotics on the Aging Digestive Tract to be Presented at Nutracon 2009
2. Altered expression of ultraconserved noncoding RNAs linked to human leukemias and carcinomas
3. Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2008 Financial Results Teleconference and Webcast
4. Union Springs Pharmaceuticals Introduces New, More Effective Respirator
5. ISTA Pharmaceuticals Announces Conference Call and Webcast of Fourth Quarter and Full-Year 2008 Financial Results
6. DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease
7. Portola Pharmaceuticals Enters Worldwide License Agreement for Development and Commercialization of Novel Antiplatelet Drug Elinogrel
8. Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
9. Biotest Pharmaceuticals Corporation Acquires Santa Fe, New Mexico Plasmapheresis Center
10. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
11. Par Pharmaceutical Announces Outcome of the Litigation With Pentech Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate ... in Latin America . ... ... ... ...
(Date:6/23/2016)... 23, 2016 The vast majority of dialysis ... facility.  Treatments are usually 3 times a week, with ... including travel time, equipment preparation and wait time.  This ... grueling for patients who are elderly and frail.  Many ... and rehabilitation centers for some duration of time. ...
(Date:6/23/2016)... June 23, 2016 The Biotechnology ... continues to present great opportunities to investors. Stock-Callers.com assesses ... Intrexon Corp. (NYSE: XON ), Vertex Pharmaceuticals ... (NASDAQ: ARNA ), and Regeneron Pharmaceuticals Inc. ... stocks and receive your complimentary trade alerts at: ...
Breaking Medicine Technology: